Xoma Corporation ( XOMA ) is a developer of antibody-based therapeutics that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on XOMA's earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Xoma Corporation could be a solid choice for investors.
Current Quarter Estimates for XOMA
In the past 30 days, 1 estimate has gone higher for Xoma Corporation while it underwent no downward revision during the same time span. The trend has been pretty favorable too, with estimates narrowing from a loss of 25 cents per share 30 days ago, to loss of 20 cents per share today, a move of 20.0%.
Current Year Estimates for XOMA
Meanwhile, Xoma Corporation's current year figures are also looking quite promising, with1 estimate moving higher in the past month, compared to no lower estimate revision during the same time period. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.07 per share 30 days ago to loss of $1.05 per share today, an increase of 2.0%.
The stock has also started to move higher lately, adding 47.0% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.